Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: A meta-analysis

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Zhou, Wen Bin ^a   Zhang, Peng Ling ^b   Liu, Xiao An ^a   Yang, Tao ^a   He, Wei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Jiangsu Province Hospital   (China)

Author keywords

breast cancer; meta analysis; musculoskeletal disorders; zoledronic acid

Indexed keywords

PLACEBO; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ARTHRALGIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; DATA BASE; HUMAN; MEDLINE; META ANALYSIS; MUSCULOSKELETAL DISEASE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPY DELAY; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; FEMALE;

BREAST NEOPLASMS; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMIDAZOLES; MUSCULOSKELETAL DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79961120717     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-72     Document Type: Article

References (33)

1. Screening for breast cancer. Elmore JG, Armstrong K, Lehman CD, Fletcher SW, JAMA 2005 293 1245 1256 10.1001/jama.293.10.1245 15755947 (Pubitemid 40327910)
2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Lancet 2005 365 1687 1717 15894097
3. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M, Lancet Oncol 2008 9 45 53 18083636
4. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A, J Clin Oncol 2007 25 486 492 10.1200/JCO.2006.08.8617 17200148 (Pubitemid 350002953)
5. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Di Cosimo S, Alimonti A, Ferretti G, Sperduti I, Carlini P, Papaldo P, Fabi A, Gelibter A, Ciccarese M, Giannarelli D, Mandal M, Milella M, Ruggeri EM, Cognetti F, Ann Oncol 2004 15 1065 1071 10.1093/annonc/mdh266 15205200 (Pubitemid 39089783)
6. Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients. Zhou WB, Yin H, Liu XA, Zha XM, Chen L, Dai JC, Tao AD, Ma JJ, Ling LJ, Wang S, BMC Cancer 2010 10 281 10.1186/1471-2407-10-281 20540745
7. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. Fuleihan Gel H, Salamoun M, Mourad YA, Chehal A, Salem Z, Mahfoud Z, Shamseddine A, J Clin Endocrinol Metab 2005 90 3209 3214 10.1210/jc.2004-1444 15769994 (Pubitemid 41014277)
8. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. Shapiro CL, Manola J, Leboff M, J Clin Oncol 2001 19 3306 3311 11454877 (Pubitemid 32642182)
9. Aromatase and its inhibitors: significance for breast cancer therapy. Simpson ER, Dowsett M, Recent Prog Horm Res 2002 57 317 338 10.1210/rp.57.1.317 12017550
10. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Jansen JP, Bergman GJ, Huels J, Olson M, Semin Arthritis Rheum 2011 40 275 284 e271-272 10.1016/j.semarthrit.2010.06.001 20828791
11. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. Mauri D, Valachis A, Polyzos NP, Tsali L, Mavroudis D, Georgoulias V, Casazza G, J Natl Compr Canc Netw 2010 8 279 286 20202461
12. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Hines SL, Mincey B, Dentchev T, Sloan JA, Perez EA, Johnson DB, Schaefer PL, Alberts S, Liu H, Kahanic S, Mazurczak MA, Nikcevich DA, Loprinzi CL, Breast Cancer Res Treat 2009 117 603 609 10.1007/s10549-009-0332-2 19214743
13. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce LL, Breast Cancer Res Treat 2009 116 433 439 10.1007/s10549-009-0432-z 19521766
14. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R, ABCSG-12 Trial Investigators, Marth C, N Engl J Med 2009 360 679 691 10.1056/NEJMoa0806285 19213681
15. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein HJ, Hudis C, Isaacs C, Schilsky R, Paskett E, Eur J Cancer 2011 47 683 689 10.1016/j.ejca.2010.11.024 21324674
16. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, Brafman L, Shane E, J Clin Oncol 2008 26 4739 4745 10.1200/JCO.2008.16.4707 18711172
17. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R, Houston SJ, Grieve RJ, Barrett-Lee PJ, Thorpe H, Breast Cancer Res Treat 2011 127 429 438 10.1007/s10549-011-1429-y 21394500
18. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, Jin L, Warsi GM, Ericson SG, Perez EA, Clin Breast Cancer 2009 9 77 85 10.3816/CBC.2009.n.015 19433387
19. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N, Coleman R, Ann Oncol 2010 21 2188 2194 10.1093/annonc/mdq217 20444845
20. Prevention of osteoporosis after breast cancer. Reid DM, Maturitas 2009 64 4 8 10.1016/j.maturitas.2009.07.008 19709826
21. The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysis. Zhou WB, Xue DQ, Liu XA, Ding Q, Wang S, J Cancer Res Clin Oncol 2011 137 1053 1060 10.1007/s00432-011-0979-z 21499874
22. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials. Zhou WB, Ding Q, Chen L, Liu XA, Wang S, Breast Cancer Res Treat 2011 128 625 631 10.1007/s10549-011-1556-5 21553116
23. Three polymorphisms in interleukin-1beta gene and risk for breast cancer: a meta-analysis. Liu X, Wang Z, Yu J, Lei G, Wang S, Breast Cancer Res Treat 2010 124 821 825 10.1007/s10549-010-0910-3 20437198
24. Quantitative synthesis in systematic reviews. Lau J, Ioannidis JP, Schmid CH, Ann Intern Med 1997 127 820 826 9382404 (Pubitemid 27465551)
25. Statistical aspects of the analysis of data from retrospective studies of disease. Mantel N, Haenszel W, J Natl Cancer Inst 1959 22 719 748 13655060
26. Meta-analysis in clinical trials. DerSimonian R, Laird N, Control Clin Trials 1986 7 177 188 10.1016/0197-2456(86)90046-2 3802833 (Pubitemid 17189972)
27. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer. Leal T, Tevaarwerk A, Love R, Stewart J, Binkley N, Eickhoff J, Parrot B, Mulkerin D, Clin Breast Cancer 2010 10 471 476 10.3816/CBC.2010.n.062 21147691
28. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy. Swenson KK, Nissen MJ, Anderson E, Shapiro A, Schousboe J, Leach J, J Support Oncol 2009 7 101 107 19507458
29. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). Kim JE, Ahn JH, Jung KH, Kim SB, Kim HJ, Lee KS, Ro JS, Park YH, Ahn JS, Im YH, Im SA, Lee MH, Kim SY, Breast Cancer Res Treat 2011 125 99 106 10.1007/s10549-010-1201-8 20922564
30. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R, J Clin Oncol 2010 28 967 975 10.1200/JCO.2009.24.5902 20065185
31. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. Hines SL, Mincey BA, Sloan JA, Thomas SP, Chottiner E, Loprinzi CL, Carlson MD, Atherton PJ, Salim M, Perez EA, J Clin Oncol 2009 27 1047 1053 10.1200/JCO.2008.19.1783 19075260
32. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Markopoulos C, Tzoracoleftherakis E, Polychronis A, Venizelos B, Dafni U, Xepapadakis G, Papadiamantis J, Zobolas V, Misitzis J, Kalogerakos K, Sarantopoulou A, Siasos N, Koukouras D, Antonopoulou Z, Lazarou S, Gogas H, Breast Cancer Res 2010 12 24 10.1186/bcr2565 20398352
33. Adverse effects of bisphosphonates: current issues. Diel IJ, Bergner R, Grotz KA, J Support Oncol 2007 5 475 482 18240669